Search
Pegdinetanib
go.drugbank.com/drugs/DB05931InvestigationalCT-322 is a proprietary Adnectin(TM) protein therapeutic that, in preclinical studies, specifically binds to vascular endothelial growth factor receptor 2 (VEGFR-2), which regulates the primary tumor angiogenesis … As a result, CT-322 blocks all known ligands for VEGFR-2.
Fraxinus pennsylvanica pollen
go.drugbank.com/drugs/DB10815ApprovedFraxinus pennsylvanica pollen is mainly used in allergenic testing.
Mixtures: Treatment Set TS128811Sodium sulfate
go.drugbank.com/drugs/DB09472ApprovedInvestigationalVet approvedSodium sulfate anhydrous disassociates in water to provide sodium ions and sulfate ions. … Sodium sulfate anhydrous is an electrolyte replenisher and is used in isosmotic solutions so that administration does not disturb normal electrolyte balance and does not lead to absorption or excretion
Solriamfetol
go.drugbank.com/drugs/DB14754ApprovedInvestigationalSolriamfetol was given FDA approval in 2019[FDA Label]. … Solriamfetol marketed under the brand name Sunosi by Jazz Pharmaceuticals in the United States is a dopamine and norepinephrine reuptake inhibitor (DNRI) indicated in treating daytime sleepiness associated
D-Serine
go.drugbank.com/drugs/DB03929ApprovedInvestigationalWithdrawnA non-essential amino acid occurring in natural form as the L-isomer. It is synthesized from GLYCINE or THREONINE. It is involved in the biosynthesis of PURINES; PYRIMIDINES; and other amino acids.
Neisseria meningitidis group Y capsular polysaccharide tetanus toxoid conjugate antigen
go.drugbank.com/drugs/DB15682ApprovedInvestigationalDehydroascorbic acid
go.drugbank.com/drugs/DB08830ExperimentalCurrently dehydroascorbic acid is an experimental drug with no known approved indications. … Dehydroascorbic acid as well as ascorbic acid are both termed Vitamin C, but the latter is the main form found in humans.
Palifermin
go.drugbank.com/drugs/DB00039ApprovedInvestigationalIt is 140 residues long, and is produced using E. coli. Palifermin was granted FDA approval on 15 December 2004.[L17933]
Infigratinib
go.drugbank.com/drugs/DB11886ApprovedInvestigationalWithdrawn[A198963] Infitratinib is a pan-FGFR inhibitor, as it is an ATP-competitive inhibitor of all four FGFR receptor subtypes. … cholangiocarcinoma in adults with a fibroblast growth factor receptor 2 (FGFR2) fusion or another rearrangement as detected by an FDA-approved test.
AP5346
go.drugbank.com/drugs/DB04992InvestigationalIt is being pursued by Access Pharmaceuticals, Inc. … AP5346 is designed to target a diaminocyclohexane platinum (Pt) moiety to tumors through pH-sensitive linkage to a 25 kDa hydroxypropylmethacrylamide polymer.